Cataracts Clinical Trial
Official title:
Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
Verified date | February 2024 |
Source | Johnson & Johnson Surgical Vision, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, multicenter, paired-eye, randomized, subject/evaluator-masked clinical investigation of the experimental EndoCoat OVD versus the control EndoCoat OVD.
Status | Completed |
Enrollment | 165 |
Est. completion date | December 21, 2023 |
Est. primary completion date | December 21, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: 1. Minimum 22 years of age 2. Cataracts for which extraction and posterior chamber IOL implantation have been planned in both eyes 3. Potential for postoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or better 4. Clear intraocular media, other than cataract 5. Availability, willingness and sufficient cognitive awareness to comply with examination procedures 6. Signed informed consent and HIPAA authorization Exclusion Criteria: 1. Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils) 2. Recent ocular trauma or ocular surgery that is not resolved/stable or may affect clinical outcomes or increase risk to the subject 3. Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery 4. Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity losses to a level worse than 20/40 Snellen during the study. 5. Prior, current, or anticipated use during the course of the 3-month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery) 6. Conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects 7. Use of systemic or ocular medications that may affect vision or IOP 8. Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/40 Snellen during the study, or in the opinion of the investigator, may confound the outcome(s) of the study 9. Poorly-controlled diabetes 10. Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). 11. Known steroid responder 12. Ocular hypertension of = 20 mmHg, medically-controlled ocular hypertension (regardless of IOP value), or glaucomatous changes in the optic nerve 13. Endothelial cell count (ECC) lower than 1800 cells/mm2 preoperatively (based on the average of the three cell counts as taken by the Konan Specular Microscope) 14. Known ocular disease or pathology that may affect visual acuity or that may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.) 15. Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes 16. Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial |
Country | Name | City | State |
---|---|---|---|
United States | Empire Eye & Laser Center | Bakersfield | California |
United States | Scott & Christie and Associates | Cranberry Township | Pennsylvania |
United States | Berkeley Eye Institute, P.A. | Houston | Texas |
United States | Eye Care Specialists | Kingston | Pennsylvania |
United States | Southern California Eye Physicians and Associates | Long Beach | California |
United States | Virginia Eye Consultants | Norfolk | Virginia |
United States | Focal Point Vision | San Antonio | Texas |
United States | Parkhurst NuVision | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Surgical Vision, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CUMULATIVE RATE OF INTRAOCULAR PRESSURE (IOP) SPIKES 30 MMHG OR GREATER | The cumulative count and proportion of eyes with an IOP spike at 3 months will be reported by OVD. Any IOP measurements of 30 mmHg or greater are to be considered a "spike". | up to 3-month follow-up | |
Primary | MEAN PERCENT ENDOTHELIAL CELL COUNT (ECC) CHANGE PREOPERATIVELY VS. POSTOPERATIVELY | The percent change in ECC from preoperative to 3 months postoperative will be reported by descriptive statistics by OVD. | up to 3-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06005675 -
User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL
|
||
Active, not recruiting |
NCT01382641 -
Show Improved Vision With the HOYA AF-1 Aspheric Intraocular Lens After Cataract Surgery
|
Phase 4 | |
Completed |
NCT01382823 -
Laser Cataract Surgery With the Femtosecond Laser Technology
|
Phase 4 | |
Completed |
NCT05991960 -
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL
|
||
Active, not recruiting |
NCT05574959 -
Clinical Investigation of the TECNIS® Next-Generation Intraocular Lens, Model DEN00V
|
N/A | |
Completed |
NCT02492659 -
Clinical Research of Femtosecond Laser-Assisted Cataract Surgery
|
N/A | |
Completed |
NCT01279031 -
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
|
Phase 4 | |
Completed |
NCT01021761 -
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT01001806 -
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
|
Phase 4 | |
Completed |
NCT01061463 -
Occupational Cataracts and Lens Opacities in Interventional Cardiology : the O'CLOC Study
|
N/A | |
Completed |
NCT00999492 -
Selection of Aspheric Diffractive Multifocal Intraocular Lens (IOLS) Based on Corneal Wavefront
|
Phase 4 | |
Completed |
NCT00542581 -
Acrysof Toric SN60T3corneal Astigmatism Between 0.75 and 1.00 D.
|
N/A | |
Completed |
NCT03708367 -
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
|
N/A | |
Recruiting |
NCT05531292 -
PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002
|
N/A | |
Completed |
NCT05058274 -
Clinical Results of a Monofocal Aspheric Bitoric Intraocular Lens With Plate Haptics in Hyperopic Eyes (HIPER-AT-TORBI)
|
||
Completed |
NCT05053399 -
Evaluation of the TECNIS Symfony® Toric Intraocular Lens
|
N/A | |
Recruiting |
NCT02639845 -
Eye Drop Application Monitor, Pilot Study
|
N/A | |
Completed |
NCT01684007 -
A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients
|
N/A | |
Completed |
NCT00827073 -
Comparison of Tetracaine 0.5% and Lidocaine 2% Jelly for Topical Phacoemulsification Cataract Surgery
|
N/A | |
Completed |
NCT00405730 -
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
|
Phase 3 |